Emory University’s Office of Critical Event Preparedness executive director Dr. Alex Isakov and Emory University’s Department of Emergency Medicine chair Dr. David Wright discuss Emory University’s newest development of a site where people who think they may have coronavirus can check to see if their symptoms align with the virus.
HOW D’OXYVA CAN HELP?
Circularity is already in Phase 3 human clinical trials with most of the top ten U.S. university research institutions with D’OXYVA for FDA approval for rapidly treating chronic conditions such as diabetic wounds and hypertension, and fighting against COVID-19 with an already FDA-approved simple, non-toxic, and widely used molecule in nearly all hospitals around the world.
D’OXYVA is the only fully noninvasive, completely painless over-the-skin microcirculatory and nerve stimulant solution that has been validated to significantly improve microcirculation.
The improvement of microcirculation, i.e., blood flow to the smallest blood vessels, benefits one’s health, immune system and overall sense of well-being in a variety of ways.
